Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study
CONCLUSIONS: Third-line chemotherapy re-use was effective in mCRC. Those with more aggressive characteristics (RAS/RAF mutant, larger tumor burden) or better efficacy of previous chemotherapy (longer PFS) were more appropriate for third-line chemotherapy, rather than anti-angiogenic monotherapy.PMID:38443891 | DOI:10.1186/s12885-024-12072-5 (Source: Cancer Control)
Source: Cancer Control - March 5, 2024 Category: Cancer & Oncology Authors: Jingjing Duan Lila Zhu Yinghui Shi Weixue Wang Tongtong Wang Tao Ning Le Zhang Ming Bai Hongli Li Rui Liu Shaohua Ge Xia Wang Yuchong Yang Zhi Ji Feixue Wang Yansha Sun Yi Ba Ting Deng Source Type: research
Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe2+ and boosting Fenton reaction
Glioma is easy to develop resistance to temozolomide (TMZ). TMZ-resistant glioma secretes interleukin-10 (IL-10) and transforming growth factor- β (TGF-β), recruiting regulatory T cell (Treg) and inhibiting the ac... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - March 5, 2024 Category: Nanotechnology Authors: Xue Li, Ying Cheng, Zhifu Yang, Qifeng Ji, Menglei Huan, Weiliang Ye, Miao Liu, Bangle Zhang, Daozhou Liu and Siyuan Zhou Tags: Research Source Type: research
Nanoparticles integrated with mild photothermal therapy and oxaliplatin for tumor chemotherapy and immunotherapy
Nanomedicine, Ahead of Print. (Source: Future Medicine: Nanomedicine)
Source: Future Medicine: Nanomedicine - March 4, 2024 Category: Nanotechnology Authors: Qiong Yi Shumin He Kai Liao Zongxiang Yue Ling Mei Source Type: research
Nanoparticles integrated with mild photothermal therapy and oxaliplatin for tumor chemotherapy and immunotherapy
Nanomedicine, Ahead of Print. (Source: Nanomedicine)
Source: Nanomedicine - March 4, 2024 Category: Nanotechnology Authors: Qiong Yi Shumin He Kai Liao Zongxiang Yue Ling Mei Source Type: research
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
CONCLUSION: Elderly U.S. Medicare beneficiaries diagnosed with DLBCL who initiated R-GemOx treatment in the R/R setting have poor overall survival, high rates of HCRU, and substantial costs.PMID:38433043 | DOI:10.1016/j.clml.2024.01.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 3, 2024 Category: Cancer & Oncology Authors: Mahek Garg Justin Puckett Sachin Kamal-Bahl Monika Raut Katherine Elizabeth Ryland Jalpa A Doshi Scott F Huntington Source Type: research
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
CONCLUSION: Elderly U.S. Medicare beneficiaries diagnosed with DLBCL who initiated R-GemOx treatment in the R/R setting have poor overall survival, high rates of HCRU, and substantial costs.PMID:38433043 | DOI:10.1016/j.clml.2024.01.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 3, 2024 Category: Cancer & Oncology Authors: Mahek Garg Justin Puckett Sachin Kamal-Bahl Monika Raut Katherine Elizabeth Ryland Jalpa A Doshi Scott F Huntington Source Type: research
High-dose oxaliplatin induces severe hypersensitivity reactions and high recurrence rates during rechallenge in patients treated with hepatic arterial infusion chemotherapy
CONCLUSIONS: The administration of OXA doses is a risk factor for OXA-induced severe hypersensitivity reactions in patients treated with HAIC (OXA). Rechallenging HAIC with OXA appears to be associated with a higher recurrence rate of the HSR.PMID:38430809 | DOI:10.1016/j.intimp.2024.111767 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 2, 2024 Category: Allergy & Immunology Authors: Baojiang Liu Song Gao Jianhai Guo Fuxin Kou Shaoxing Liu Xin Zhang Aiwei Feng Xiaodong Wang Guang Cao Liang Xu Hui Chen Peng Liu Haifeng Xu Qinzong Gao Renjie Yang Xu Zhu Source Type: research
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice
In this study, we aimed to evaluate the impact of acute exercise before treatment administration on tumor growth in a mice model of MC38 colorectal cancer receiving an immune checkpoint inhibitor (ICI) and chemotherapy. Six-week-old mice injected with colorectal cancer cells (MC38) were randomized in 4 groups: control (CTRL), immuno-chemotherapy (TRT), exercise (EXE) and combined intervention (TRT/EXE). Both TRT and TRT-EXE received ICI: anti-PD1-1 (1 injection/week) and capecitabine + oxaliplatin (5 times a week) for 1 week (experimentation 1), 3 weeks (experimentation 2). TRT-EXE and EXE groups were submitted to 50 minut...
Source: Atherosclerosis - March 1, 2024 Category: Cardiology Authors: Manon Gouez Am élie Rébillard Amandine Thomas Sabine Beaumel Eva-Laure Matera Etienne Gouraud Luz Orfila Brice Martin Olivia P érol C édric Chaveroux Erica N Chirico Charles Dumontet B éatrice Fervers Vincent Pialoux Source Type: research
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G
CONCLUSIONS: This study did not meet the primary endpoint. Hence, FOLFIRI plus AFL should not be used after FTD/TPI plus BEV for metastatic colorectal cancer. Further studies are needed to determine factors not targeted by AFL that may affect the efficacy of the treatment.CLINICAL TRIAL REGISTRATION: jRCTs041190100.PMID:38427280 | DOI:10.1007/s11523-024-01043-2 (Source: Cancer Control)
Source: Cancer Control - March 1, 2024 Category: Cancer & Oncology Authors: Toshihiko Matsumoto Yoshiyuki Yamamoto Masahito Kotaka Toshiki Masuishi Yasushi Tsuji Hirokazu Shoji Kenro Hirata Takao Tsuduki Akitaka Makiyama Naoki Izawa Naoki Takahashi Masahiro Tsuda Hisateru Yasui Takashi Ohta Yosuke Kito Satoshi Otsu Shuichi Hirona Source Type: research
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice
In this study, we aimed to evaluate the impact of acute exercise before treatment administration on tumor growth in a mice model of MC38 colorectal cancer receiving an immune checkpoint inhibitor (ICI) and chemotherapy. Six-week-old mice injected with colorectal cancer cells (MC38) were randomized in 4 groups: control (CTRL), immuno-chemotherapy (TRT), exercise (EXE) and combined intervention (TRT/EXE). Both TRT and TRT-EXE received ICI: anti-PD1-1 (1 injection/week) and capecitabine + oxaliplatin (5 times a week) for 1 week (experimentation 1), 3 weeks (experimentation 2). TRT-EXE and EXE groups were submitted to 50 minut...
Source: Cancer Control - March 1, 2024 Category: Cancer & Oncology Authors: Manon Gouez Am élie Rébillard Amandine Thomas Sabine Beaumel Eva-Laure Matera Etienne Gouraud Luz Orfila Brice Martin Olivia P érol C édric Chaveroux Erica N Chirico Charles Dumontet B éatrice Fervers Vincent Pialoux Source Type: research
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice
In this study, we aimed to evaluate the impact of acute exercise before treatment administration on tumor growth in a mice model of MC38 colorectal cancer receiving an immune checkpoint inhibitor (ICI) and chemotherapy. Six-week-old mice injected with colorectal cancer cells (MC38) were randomized in 4 groups: control (CTRL), immuno-chemotherapy (TRT), exercise (EXE) and combined intervention (TRT/EXE). Both TRT and TRT-EXE received ICI: anti-PD1-1 (1 injection/week) and capecitabine + oxaliplatin (5 times a week) for 1 week (experimentation 1), 3 weeks (experimentation 2). TRT-EXE and EXE groups were submitted to 50 minut...
Source: Atherosclerosis - March 1, 2024 Category: Cardiology Authors: Manon Gouez Am élie Rébillard Amandine Thomas Sabine Beaumel Eva-Laure Matera Etienne Gouraud Luz Orfila Brice Martin Olivia P érol C édric Chaveroux Erica N Chirico Charles Dumontet B éatrice Fervers Vincent Pialoux Source Type: research
LABS score- a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study
CONCLUSIONS: The proposed LABS score could discriminate patients who would derive benefit from FOLFOX4 chemotherapy. FOLFOX4 chemotherapy is an option for patients who cannot receive immunotherapy and targeted therapy, particularly those with a low-risk score. However, further validation of this model via larger cohorts is warranted.PMID:38429725 | DOI:10.1186/s12885-024-12040-z (Source: Cancer Control)
Source: Cancer Control - March 1, 2024 Category: Cancer & Oncology Authors: Jirapat Wonglhow Patrapim Sunpaweravong Chirawadee Sathitruangsak Arunee Dechaphunkul Source Type: research
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G
CONCLUSIONS: This study did not meet the primary endpoint. Hence, FOLFIRI plus AFL should not be used after FTD/TPI plus BEV for metastatic colorectal cancer. Further studies are needed to determine factors not targeted by AFL that may affect the efficacy of the treatment.CLINICAL TRIAL REGISTRATION: jRCTs041190100.PMID:38427280 | DOI:10.1007/s11523-024-01043-2 (Source: Cancer Control)
Source: Cancer Control - March 1, 2024 Category: Cancer & Oncology Authors: Toshihiko Matsumoto Yoshiyuki Yamamoto Masahito Kotaka Toshiki Masuishi Yasushi Tsuji Hirokazu Shoji Kenro Hirata Takao Tsuduki Akitaka Makiyama Naoki Izawa Naoki Takahashi Masahiro Tsuda Hisateru Yasui Takashi Ohta Yosuke Kito Satoshi Otsu Shuichi Hirona Source Type: research
Innovative Nanoparticulate Strategies in Colon Cancer Treatment: A Paradigm Shift
AAPS PharmSciTech. 2024 Mar 1;25(3):52. doi: 10.1208/s12249-024-02759-0.ABSTRACTAs a major public health issue, colorectal cancer causes 9.4% of total cancer-related deaths and comprises 10% of new cancer diagnoses worldwide. In the year 2023, an estimated 153,020 people are expected to receive an identification of colorectal cancer (CRC), resulting in roughly 52,550 fatalities anticipated as a result of this illness. Among those impacted, approximately 19,550 cases and 3750 deaths are projected to occur in individuals under the age of 50. Irinotecan (IRN) is a compound derived from the chemical structure of camptothecin, ...
Source: AAPS PharmSciTech - March 1, 2024 Category: Drugs & Pharmacology Authors: Rati Yadav Rohit Bhawale Vaibhavi Srivastava Ekta Pardhi Harshada Anil Bhalerao Rajesh Sonti Neelesh Kumar Mehra Source Type: research
Innovative Nanoparticulate Strategies in Colon Cancer Treatment: A Paradigm Shift
AAPS PharmSciTech. 2024 Mar 1;25(3):52. doi: 10.1208/s12249-024-02759-0.ABSTRACTAs a major public health issue, colorectal cancer causes 9.4% of total cancer-related deaths and comprises 10% of new cancer diagnoses worldwide. In the year 2023, an estimated 153,020 people are expected to receive an identification of colorectal cancer (CRC), resulting in roughly 52,550 fatalities anticipated as a result of this illness. Among those impacted, approximately 19,550 cases and 3750 deaths are projected to occur in individuals under the age of 50. Irinotecan (IRN) is a compound derived from the chemical structure of camptothecin, ...
Source: AAPS PharmSciTech - March 1, 2024 Category: Drugs & Pharmacology Authors: Rati Yadav Rohit Bhawale Vaibhavi Srivastava Ekta Pardhi Harshada Anil Bhalerao Rajesh Sonti Neelesh Kumar Mehra Source Type: research
